Toll Free: 1-888-928-9744

Immunovaccine, Inc. - Product Pipeline Review - 2016

Published: Jul, 2016 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immunovaccine, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Immunovaccine, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunovaccine, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Immunovaccine, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Immunovaccine, Inc.
- The report provides overview of Immunovaccine, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Immunovaccine, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Immunovaccine, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Immunovaccine, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Immunovaccine, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immunovaccine, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Immunovaccine, Inc. Snapshot 5 Immunovaccine, Inc. Overview 5 Key Information 5 Key Facts 5 Immunovaccine, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Immunovaccine, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Immunovaccine, Inc. - Pipeline Products Glance 14 Immunovaccine, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Immunovaccine, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Immunovaccine, Inc. - Drug Profiles 17 DPX-Survivac 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 DPX-RSV 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vaccine for Cocaine Addiction 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 DPX-Ebola 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DPXE-7 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 malaria vaccine 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Zika virus vaccine 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Immunovaccine, Inc. - Pipeline Analysis 27 Immunovaccine, Inc. - Pipeline Products by Target 27 Immunovaccine, Inc. - Pipeline Products by Route of Administration 28 Immunovaccine, Inc. - Pipeline Products by Molecule Type 29 Immunovaccine, Inc. - Recent Pipeline Updates 30 Immunovaccine, Inc. - Dormant Projects 36 Immunovaccine, Inc. - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 Pseudomonas vaccine 37 Immunovaccine, Inc. - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Immunovaccine, Inc., Key Information 5 Immunovaccine, Inc., Key Facts 5 Immunovaccine, Inc. - Pipeline by Indication, 2016 7 Immunovaccine, Inc. - Pipeline by Stage of Development, 2016 8 Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2016 9 Immunovaccine, Inc. - Partnered Products in Pipeline, 2016 10 Immunovaccine, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 11 Immunovaccine, Inc. - Out-Licensed Products in Pipeline, 2016 12 Immunovaccine, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Immunovaccine, Inc. - Phase II, 2016 14 Immunovaccine, Inc. - Phase I, 2016 15 Immunovaccine, Inc. - Preclinical, 2016 16 Immunovaccine, Inc. - Pipeline by Target, 2016 27 Immunovaccine, Inc. - Pipeline by Route of Administration, 2016 28 Immunovaccine, Inc. - Pipeline by Molecule Type, 2016 29 Immunovaccine, Inc. - Recent Pipeline Updates, 2016 30 Immunovaccine, Inc. - Dormant Developmental Projects,2016 36 Immunovaccine, Inc. - Discontinued Pipeline Products, 2016 37



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify